Close menu




November 18th, 2025 | 07:10 CET

Takeover fever! LAURION Mineral Exploration, Evotec, and Mutares are tempting investors to get on board!

  • Mining
  • Commodities
  • Gold
  • Defense
  • Biotechnology
Photo credits: pixabay.com

M&A – mergers and acquisitions - remain powerful performance drivers for shareholders of potential takeover targets. But companies that acquire others also benefit from increased growth, access to new markets and technologies, and cost synergies. According to a recent study by Bain & Company, the majority of M&A activity in the current year, amounting to around USD 265 billion, has taken place in the energy and commodities sectors. In healthcare and life sciences, deals with a volume of USD 107 billion were recorded. So who could the next takeover candidates be?

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: LAURION MINERAL EXPLORATION INC | CA5193221010 , EVOTEC SE INH O.N. | DE0005664809 , MUTARES KGAA NA O.N. | DE000A2NB650

Table of contents:


    LAURION Mineral Exploration – A guarantee for shareholder value

    Gold prices of over USD 4,000 per ounce, a sustained long-term upward trend in the precious metal, and the coffers of the major players bulging with cash for acquisitions already provide an excellent backdrop for LAURION Mineral Exploration. The Company is advancing the Ishkōday Gold and Base Metal Project in the Canadian province of Ontario.

    The 57.43 sq km project is located 220 km northeast of Thunder Bay in the resource-rich Beardmore-Geraldton Greenstone Belt. Ishkōday hosts gold, silver, zinc, and copper mineralization along a 6 x 2.5 km corridor. To date, nearly 100,000 meters in 462 holes have been drilled, including multiple very high-grade intercepts. Outstanding results were achieved as part of the 7,000-meter 2025 summer drill program. In the Cyril Knight Showing Zone, a whopping 32.47 g/t gold was detected over 1.90 m, including 0.90 m grading 67.80 g/t gold.

    Recent drill results indicate the mineralized zone of the historical Brenbar Mine Area may extend further to the north and northeast. The evaluation confirms that mineralization continues both in the targeted areas and at depth.

    The Company will continue to explore the Ishkōday Project in the coming year and plans to drill 7,000 to 10,000 meters. With further progress and new data confirming the high-grade mineralization, expanding or better defining it, the stock is gradually moving up the list of potential takeover candidates - a scenario that management openly keeps in view. The fact that "family and friends" hold nearly three-quarters of the shares guarantees that only measures that increase shareholder value will be taken. Despite its progress, the stock remains under the radar for many investors. A first step to broaden visibility was the recent Frankfurt listing at the end of October. Based on a share price of CAD 0.30, LAURION currently carries a valuation of around CAD 80 million.

    Evotec – Insiders buying again

    Evotec is a recognized heavyweight in the biotech sector. The Company's core strength lies in the systematic discovery and early development of new active ingredients based on a technology-driven, scalable platform. This model makes its services highly attractive to major pharmaceutical companies – Evotec collaborates with all leading global players – as well as to more than 800 biotech firms and numerous academic institutions.

    Disappointing operating developments due to weak demand in the market for early-stage drug research have been putting pressure on the share price for months. Management is attempting to counter the negative trend with strategic adjustments and cost savings, but these measures have not yet borne fruit. The share price has successfully tested the support level of EUR 5 for the second time this year.

    Most recently, both the Management Board and Supervisory Board purchased treasury shares. With its current service portfolio and a market capitalization of around EUR 900 million, Evotec is definitely a takeover candidate. Analysts place the average price target at just over EUR 9, giving the share a price potential of over 70% over a 12-month horizon.

    Mutares – Upside of over 50% and generous dividends

    Mutares makes its money from buying and selling corporate investments. The private equity holding company, with 15 regional offices worldwide, buys companies in transition that show significant potential for operational improvement and sells them again after stabilization and repositioning. A few days ago, the Company delighted market participants with positive quarterly figures.

    The fact that Mutares expects further transactions before the end of the year certainly also had a positive effect. It can therefore be safely assumed that the Company will achieve its annual targets. Next summer, shareholders can once again look forward to a generous dividend. Last year, this stood at EUR 2, which is also likely to be the new minimum target. The share price is expected to quickly recover from the current dip caused by the profit warning from Steyr Motors. Analysts estimate the share price potential at over 50%! The dividend yield is over 7%.


    There are many ways for shareholders to benefit from the M&A merry-go-round. At Mutares, buying and selling companies is part of everyday business. With potential takeover targets such as LAURION Mineral Exploration and Evotec, investors can acquire attractively valued companies and simply wait for a strategic buyer to make a move. LAURION Mineral Exploration controls a high-quality asset whose value should continue to grow through ongoing drilling programs and further development.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Fabian Lorenz on August 24th, 2026 | 07:35 CEST

    Share Price Surges and Buy Ratings: New Price Target for Almonty as CTS EVENTIM and BioNTech Stage Comebacks

    • Tungsten
    • CriticalMetals
    • Biotechnology
    • entertainment

    What a comeback! Almonty's share price surged by more than 50% in August! There are good reasons for the rally. Tungsten is in short supply in the West and is urgently needed due to the ramp-up in weapons production in the US. In addition, Almonty has released convincing quarterly results and announced a share buyback program. Analysts have recently nearly doubled their price target. BioNTech's share price jump of over 25% is less attributable to the biotech company itself; the stock has benefited from the breakthrough achieved by rival Moderna. Meanwhile, long-term performer CTS EVENTIM also made a comeback last week. Does this mean the stock is returning to its long-term uptrend? Analysts recommend the share as a "Buy".

    Read

    Commented by Matthias Schomber on August 24th, 2026 | 07:30 CEST

    Return Opportunities in Defence, Hydrogen and GreenTech: How Deutz, Nel ASA and MustGrow Biologics Are Gearing Up for a Breakout!

    • biologicals
    • agritech
    • GreenTech
    • Defense

    Created and Published on Behalf of MustGrow Biologics Corp.

    Trump's hard-line stance in the Iran conflict and the blockade of the Strait of Hormuz have been keeping the financial markets on edge for weeks and months. This issue will likely remain with us for quite some time. However, these geopolitical crises are currently causing massive shifts in market weightings, with defence-related stocks gaining renewed momentum while many former "hydrogen hype" stocks continue to lose ground. Deutz AG, for example, is pivoting toward the defence technology sector with billion-euro acquisitions, thereby striking exactly the right chord with current market sentiment. Nel ASA, by contrast, is experiencing the opposite: despite a strong order book, weak margins continue to weigh on the stock. Away from these two companies, MustGrow Biologics, a smaller company operating in a niche market, is making headway. The Canadian agri-biotech specialist is making strides in sustainable crop protection and may be on the verge of a technical breakout.

    Read

    Commented by Lars Winter on August 21st, 2026 | 09:00 CEST

    A.H.T. Syngas on the Verge of a Breakthrough? Tonies Booms, RENK Sparks Takeover Speculation - Three Stocks to Watch

    • decarbonization
    • Energy
    • syngas
    • Defense
    • consumergoods
    • cleantech

    From a celebrated high-flyer to a forgotten micro-cap: A.H.T. Syngas has seen its share price plunge. But new projects, a growing pipeline, and a focus on scalable energy solutions are sparking fresh optimism. If the operational turnaround succeeds, the stock has the potential to multiply in value. Tonies also still offers upside potential. The manufacturer of the popular audio cubes for children continues to deliver strong growth and recently reported solid results. Meanwhile, transmission-system manufacturer and defense contractor RENK is also impressing operationally. The company is sitting on a record order backlog and is even considered a potential takeover target. Three stocks with completely different risk profiles—but each with clear catalysts driving their prices. We take a closer look at this trio in our stock review.

    Read